Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Heavy alcohol use among people with hepatitis B or C increased the risk of liver cancer.
A steep rise in drug overdose deaths during the pandemic led to greater availability of donor organs.
Higher daily alcohol consumption was linked to greater risk for MAFLD.
Three checkpoint inhibitors reduce the risk of death for patients with hard-to-treat liver and biliary tract cancers.
A majority of people with alcohol-related liver cirrhosis may have normal ALT levels.
From 1995 to 2016, hepatocellular carcinoma incidence in rural populations climbed by 218%.
An extra booster dose raised antibody levels in one third of people with organ transplants, but many remain unprotected.
Even lower levels of alcohol use by women puts them at a greater risk for several severe illnesses.
The early cancer is detected, the easier it is to treat.
Alcoholism-related liver disease was a growing problem even before COVID-19, but the pandemic has dramatically added to the toll.
People with advanced liver cirrhosis are at greater risk for severe COVID-19 illness and death.
Liver complications, heart disease and non-liver cancers also account for most deaths among people with hepatitis B or C.
Transplants due to hepatitis C have dropped dramatically, especially among people with liver cancer.
Hepatitis B and C, non-alcoholic steatohepatitis (NASH) and alcohol-related liver disease are the main causes of liver cancer and cirrhosis.
Better treatments for hepatitis B and C and a lack of such advances for fatty liver or alcoholic liver disease are driving outcomes.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.